Skip to content
Drug Policy Watch™
LatestTracking drug policy in all 50 states and Congress, updated every morning.See all ›
Drug Policy Watch · State Brief 2026

Nebraska

Snapshot (structured)

Adult-use cannabis
Illegal. No legalization. Possession of small amounts is a civil infraction for a first offense, but there is no legal adult-use market. A 2026 citizen initiative to create a constitutional right to use cannabis is in signature gathering, with a July 3, 2026 deadline. https://news.ballotpedia.org/2025/08/29/proponents-file-recreational-marijuana-initiative-in-nebraska-for-2026-ballot-the-fifth-initiative-attempt-since-2018/
Medical cannabis
Legal by voter initiative (November 2024), but not yet operational. Certified patients may possess up to 5 ounces now, no legal sales yet, dispensaries not expected before fall 2026 at the earliest. https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/
Home grow
Not permitted. The 2024 medical measures do not authorize home cultivation. https://www.mpp.org/states/nebraska/
Intoxicating hemp / hemp THC
Currently broadly available (delta-8, THCA, etc.); a state ban (LB316) is a 2026 carryover bill, and the federal November 12, 2026 redefinition will sharply restrict these products. https://nebraskaexaminer.com/2025/05/30/proposal-to-ban-most-thc-consumable-hemp-products-in-nebraska-delayed-until-at-least-2026/
Psychedelics
Illegal. No decriminalization or therapeutic-access law; no confirmed 2026 bill found. https://www.mpp.org/states/nebraska/
Broad decriminalization
Limited. First-offense cannabis possession (up to 1 ounce) is a civil infraction, not jail; broader drug decriminalization does not exist. https://nebraskastatecannabis.org/laws
Harm reduction
Partial. Naloxone and fentanyl test strips are legal and distributable; syringe services programs remain not authorized statewide after a gubernatorial veto. https://www.rstreet.org/outreach/testimony-in-support-of-allowing-local-jurisdictions-to-authorize-syringe-services-programs-in-nebraska/
Governor (party)
Jim Pillen (Republican). https://governor.nebraska.gov/gov-pillen-signs-emergency-regulations-guiding-implementation-medical-cannabis
Legislature control
Officially nonpartisan unicameral; functionally Republican-leaning, roughly 33 Republican to 15 Democratic plus 1 independent among 49 members. https://ballotpedia.org/Nebraska_State_Senate_(Unicameral)
Citizen ballot initiatives allowed
Yes. Nebraska allows citizen-initiated statutes and constitutional amendments. https://ballotpedia.org/Nebraska_Marijuana_Legalization_Initiative_(2026)
Enclosure pressure score
5/5

Cannabis

Adult-use cannabis remains illegal in Nebraska in 2026. There is no legal recreational market. A first-offense possession of up to 1 ounce is treated as a civil infraction with a fine rather than jail, a narrow decriminalization that predates the recent measures. https://nebraskastatecannabis.org/laws

Medical cannabis became legal through two voter initiatives approved on November 5, 2024: Initiative 437 (legalizing patient possession with a health care practitioner recommendation) and Initiative 438 (creating the Nebraska Medical Cannabis Commission to regulate the supply chain). They passed with roughly 71% and 67% of the vote and took effect December 12, 2024. https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/ and https://en.wikipedia.org/wiki/2024_Nebraska_Initiative_437

Implementation has been heavily contested. Governor Jim Pillen and Attorney General Mike Hilgers, both Republicans, publicly questioned the measures' validity under federal law and the state constitution. https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/ Former state senator John Kuehn (a longtime opponent) has brought repeated lawsuits to void the laws on federal preemption grounds; Lancaster County District Judge Susan Strong dismissed his suit in June 2025 for lack of standing, and the Nebraska Supreme Court heard a second appeal on April 27, 2026, with no final ruling confirmed at the time of writing. https://nebraskaexaminer.com/2026/04/27/nebraska-supreme-court-hears-appeal-in-medical-cannabis-federal-preemption-case/

Status of the program: Initiative 437 requires no implementing action, so certified patients may currently possess up to 5 ounces; recommendations need not come from an in-state physician. https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/ However, no legal sales exist yet. The Medical Cannabis Commission issued its first cultivation licenses (reported as four licensed cultivators, each capped at 1,250 plants) and, as of early 2026, was not accepting other application types. https://www.mpp.org/states/nebraska/ The commission unanimously approved formal supply-chain regulations on April 13, 2026, sending them to AG Hilgers for legal review and then to Governor Pillen for final approval. Update, July 18, 2026: AG Hilgers approved the regulations on June 30, 2026 and Governor Pillen signed them on July 1, 2026; the permanent rules are now in effect and business licensing is underway, though no dispensaries are operating yet (https://governor.nebraska.gov/gov-pillen-approves-permanent-regulations-medical-marijuana). https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/

Market structure: The draft rules impose a 4-year Nebraska residency requirement (at least 51% ownership by U.S. citizens who have lived in the state for four consecutive years), a one-license-per-judicial-district cap for dispensaries, business-plan and facility-design standards, and 1,000-foot buffers from schools, daycares, and youth centers. The rules reportedly ban raw plant material, smoking and vaping products, flavored items, and infused food or drink, and restrict dispensary access to patients with in-state recommendations. https://www.cann.dev/nebraska-cannabis-retail-february-2026/ and https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/ These residency and license-cap features sharply limit multistate-operator entry and concentrate competition in the Omaha and Lincoln districts. https://www.cann.dev/nebraska-cannabis-retail-february-2026/

Home grow is not authorized. https://www.mpp.org/states/nebraska/

Key 2026 actions: The Legislature passed LB1235, its first-ever medical cannabis statute, giving the commission authority to set application fees and require fingerprint background checks; an amendment stripped controversial language that would have curtailed patient protections. https://nebraskaexaminer.com/briefs/history-made-nebraska-legislature-passes-first-medical-cannabis-law-after-decade-delay/ A separate bill to protect health care providers who recommend cannabis (LB933, carried by Sen. John Cavanaugh) advanced but was pulled in April 2026 after hostile amendments; advocates warn this may deter in-state physicians from participating. https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/ Whether Pillen has signed LB1235 or the formal regulations is unconfirmed as of this writing.

Federal backdrop: Nebraska Examiner reporting indicates the U.S. DOJ moved to downgrade cannabis to Schedule III in April 2026, and that Nebraska, previously left off congressional medical-cannabis protections from DOJ interference, could soon gain such protection. These are reported developments; specifics should be confirmed against the live sources. https://nebraskaexaminer.com/2026/04/23/nebraska-advocates-cheer-as-doj-downgrades-medical-cannabis-to-schedule-iii-drug/ and https://nebraskaexaminer.com/2026/04/30/nebraska-medical-cannabis-laws-could-soon-be-protected-from-federal-interference-after-all/

Hemp

Intoxicating hemp-derived products (delta-8, delta-10, THCA, HHC, and similar) have been broadly sold in Nebraska under the gap left by the 2018 federal Farm Bill. https://www.atlrx.com/blogs/delta-8/is-delta-8-legal-in-nebraska/

State action: In January 2025, Sen. Kathleen Kauth introduced LB316, backed by AG Hilgers, to redefine hemp using a total-THC standard (no more than 0.3% total THC, counting all THC isomers rather than only delta-9), which would effectively ban most intoxicating hemp products. Opponents, including Sens. John Cavanaugh and Wendy DeBoer of Omaha, blocked it, warning it could turn possession of a gummy into a felony; the bill ran out of time in 2025 and carried over for the 2026 session. https://nebraskaexaminer.com/2025/05/30/proposal-to-ban-most-thc-consumable-hemp-products-in-nebraska-delayed-until-at-least-2026/ and https://www.billtrack50.com/billdetail/1785559 The current status of LB316 in the 2026 session (whether it advanced, stalled, or passed) is unconfirmed; consult the live tracker. https://www.billtrack50.com/billdetail/1785559

Federal exposure and the November 12, 2026 deadline: On November 12, 2025, H.R. 5371 (the Continuing Appropriations and Extensions Act, 2026) was signed into law, redefining hemp federally with a total-THC cap (delta-9 plus 0.877 times THCA) of 0.3% by dry weight and capping finished consumable hemp products at 0.4 mg total THC per container. These provisions take effect November 12, 2026, after which most current intoxicating hemp products would be non-compliant and exposed to federal Controlled Substances Act enforcement. https://www.congress.gov/crs-product/IN12620 and https://vicentellp.com/insights/2026-federal-hemp-ban-what-it-means-for-the-future-of-consumable-hemp-products/ Because Nebraska has no protective state framework legalizing these products, the federal change is likely to be the binding constraint regardless of the fate of LB316. https://thehazeconnect.com/blogs/learn/november-12-2026-federal-hemp-deadline-every-state

Psychedelics

Psychedelics (psilocybin, LSD, and similar) remain illegal in Nebraska. No statewide decriminalization or therapeutic-access program exists. No confirmed 2026 psychedelics bill was located in this research; if one exists it is unconfirmed. https://www.mpp.org/states/nebraska/ and https://worldpopulationreview.com/state-rankings/mushroom-laws-by-state

Broader drug policy

Decriminalization: Nebraska decriminalized only first-offense possession of up to 1 ounce of cannabis (a civil infraction). There is no broad drug decriminalization. https://nebraskastatecannabis.org/laws

Harm reduction: - Naloxone: Legal and broadly accessible. Laws 2025 LB195 defines opioid overdose reversal medication to include naloxone and nalmefene, obtainable by prescription, from a health professional, or over the counter. https://www.rstreet.org/outreach/testimony-in-support-of-allowing-local-jurisdictions-to-authorize-syringe-services-programs-in-nebraska/ - Fentanyl test strips: Legal. Pharmacists and retailers may sell them over the counter, and local public health departments may distribute them without a fee. https://www.rstreet.org/outreach/testimony-in-support-of-allowing-local-jurisdictions-to-authorize-syringe-services-programs-in-nebraska/ - Syringe services programs (SSPs): Not authorized statewide. A 2024 effort (LB307) passed the Legislature 30-7 but was vetoed by Gov. Pillen and the veto was sustained; subsequent bills to let local jurisdictions opt in (for example LB165) have been introduced. The 2026 status of any SSP authorization bill is unconfirmed. https://update.legislature.ne.gov/?p=35936 and https://www.rstreet.org/outreach/testimony-in-support-of-allowing-local-jurisdictions-to-authorize-syringe-services-programs-in-nebraska/

Sentencing and expungement: No cannabis-specific automatic expungement or record-sealing program has been identified in the 2024 measures or in 2025-2026 legislation. This is unconfirmed and should be verified against the legislature's records.

Overdose and treatment policy: Specific 2025-2026 overdose-response or treatment-funding actions beyond the naloxone/test-strip framework were not located in this research and are unconfirmed.

Political landscape

Governor: Jim Pillen (Republican). He has tried to position himself between outright opposition and implementation, signing emergency/temporary medical cannabis regulations before the July 1, 2025 deadline and setting aside more than $2 million in budget adjustments for the Liquor Control Commission (which houses the Medical Cannabis Commission), while framing medical access partly as a way to forestall recreational legalization. https://governor.nebraska.gov/gov-pillen-signs-emergency-regulations-guiding-implementation-medical-cannabis and https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/

Attorney General: Mike Hilgers (Republican), the most prominent named opponent. He has publicly questioned the validity of the 2024 measures, led a news conference against implementing legislation (LB677) in May 2025, and warned he will review complaints against medical professionals who recommend cannabis, which advocates say has chilled in-state physician participation. https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/

Legislature: Officially nonpartisan unicameral with 49 members. By party affiliation it leans Republican (roughly 33 Republicans, 15 Democrats, 1 independent). Speaker: John Arch. https://ballotpedia.org/Nebraska_State_Senate_(Unicameral) and https://en.wikipedia.org/wiki/Nebraska_Legislature

Key committees: The General Affairs Committee handles cannabis and liquor matters; its chair is reported as Sen. Rick Holdcroft (unconfirmed at the level of current term and should be verified). https://nebraskalegislature.gov/committees/landing_pages/index.php?cid=6

Named reform champions: Sen. John Cavanaugh of Omaha (provider-protection bill LB933, opposition to the hemp ban) and Sen. Wendy DeBoer of Omaha (opposition to LB316). https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/ and https://nebraskaexaminer.com/2025/05/30/proposal-to-ban-most-thc-consumable-hemp-products-in-nebraska-delayed-until-at-least-2026/ Advocacy is led by Crista Eggers and Nebraskans for Medical Marijuana, the group behind the 2024 petition drive. https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/

Named opponents: AG Mike Hilgers, former Sen. John Kuehn (litigation), and Sen. Kathleen Kauth (hemp ban LB316). https://nebraskaexaminer.com/2026/04/27/nebraska-supreme-court-hears-appeal-in-medical-cannabis-federal-preemption-case/ and https://nebraskaexaminer.com/2025/05/30/proposal-to-ban-most-thc-consumable-hemp-products-in-nebraska-delayed-until-at-least-2026/

Ballot initiatives

Nebraska allows citizen-initiated statutes and constitutional amendments. The 2024 medical cannabis measures (Initiatives 437 and 438) were citizen initiatives. https://en.wikipedia.org/wiki/2024_Nebraska_Initiative_437

Pending 2026 measure: An initiative to amend the Nebraska Constitution to establish a "right to use all plants in the genus Cannabis" for adults 21 and older was filed August 18, 2025 by Bill Hawkins of the Nebraska Hemp Company. It is the fifth recreational-cannabis initiative attempt since 2018; none has previously qualified. To make the November 2026 ballot, organizers must gather valid signatures from about 10% of registered voters (roughly 123,000), with a distribution requirement of at least 5% of registered voters in 38 of 93 counties. The signature deadline is July 3, 2026, and as of mid-2026 it is in active signature gathering. https://news.ballotpedia.org/2025/08/29/proponents-file-recreational-marijuana-initiative-in-nebraska-for-2026-ballot-the-fifth-initiative-attempt-since-2018/ and https://ballotpedia.org/Nebraska_Marijuana_Legalization_Initiative_(2026)

Equity and expungement

No social-equity licensing provisions have been identified in the 2024 measures or the draft regulations; on the contrary, the 4-year residency and 51% citizen-ownership requirements function as barriers that favor established, capitalized in-state operators. https://www.cann.dev/nebraska-cannabis-retail-february-2026/ No automatic or petition-based cannabis expungement or record-sealing program tied to the measures has been identified; this is unconfirmed and should be verified against the legislature's records. The practical effect is that small operators face high entry thresholds and there is no identified relief pathway for prior cannabis convictions.

Market and barriers

Hard numbers where available: - Cultivation: First cultivation licenses issued (reported as four cultivators), each capped at 1,250 plants. https://www.mpp.org/states/nebraska/ - Dispensary cap: One license per judicial district (statewide cap structure), concentrating competition in Omaha and Lincoln. https://www.cann.dev/nebraska-cannabis-retail-february-2026/ - Residency/ownership: At least 51% ownership by U.S. citizens who have lived in Nebraska for four consecutive years. https://www.cann.dev/nebraska-cannabis-retail-february-2026/ - Buffers: Dispensaries banned within 1,000 feet of schools, daycares, and youth centers. https://www.cann.dev/nebraska-cannabis-retail-february-2026/ - Application fees: LB1235 authorizes the commission to set fees; specific dollar amounts were not finalized in the sources reviewed and are unconfirmed. https://nebraskaexaminer.com/briefs/history-made-nebraska-legislature-passes-first-medical-cannabis-law-after-decade-delay/ - Taxes: A medical cannabis tax rate was not identified in the sources reviewed and is unconfirmed. - Product restrictions: Draft rules reportedly ban raw plant material, smoking/vaping products, flavored items, and infused food or drink, narrowing the addressable market to a limited set of product forms. https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/

Enclosure read

Who is being fenced out: out-of-state and undercapitalized operators (via the 4-year residency and 51% citizenship rules), patients without in-state physician recommendations (dispensary access is restricted to in-state recommendations while almost no Nebraska physicians have enrolled, partly due to fear of AG enforcement), home growers (no cultivation right), and the intoxicating hemp sector (facing both a possible state ban and the November 12, 2026 federal cap). https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/ and https://www.cann.dev/nebraska-cannabis-retail-february-2026/

Who is consolidating: a small number of in-state, capitalized cultivators and the holders of the one-per-district dispensary licenses, with the Liquor Control Commission (the same three commissioners) controlling the regulatory chokepoint. https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/

Justification for score 5/5 (corrected July 18, 2026; an earlier version of this brief scored Nebraska 4): Nebraska is fully fenced. Voters approved medical cannabis by wide margins, yet the executive branch (AG opposition, litigation, a chilled physician pool), restrictive residency and license-cap rules, a narrow product list, no home grow, and no social equity combine to block the market the voters ordered. Under the July 2026 re-score, a right without a supply is not access: patient possession is lawful, but with almost no enrolled physicians and no operating dispensaries there is no legal way for most patients to obtain what they may possess. A voter-approved commons blocked at the gate by the state's own officers is not a door ajar. The live recreational initiative and the federal Schedule III track are prospects, not access, and the imminent federal hemp crackdown closes the one informal lane that remained.

What to watch next

Regulators

Federal exposure (2026)

Nebraska's exposure to federal drug policy in 2026 runs through five levers, and for this state the most consequential are the hemp redefinition and the gap between a paper rescheduling and a market that does not yet exist.

Rescheduling and 280E. In April 2026 the DOJ/DEA order moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III, leaving recreational cannabis on Schedule I. For the medical category, Schedule III ends the application of Internal Revenue Code Section 280E, which otherwise bars cannabis businesses from deducting ordinary business expenses and effectively taxes them on gross rather than net income. The catch in Nebraska is that 280E relief is only worth something to a business that has taxable sales. Nebraska's voter-approved 2024 medical program is contested (a Nebraska Supreme Court preemption appeal argued April 27, 2026 was still pending) and not yet operational: a few cultivators have been licensed but no dispensary has opened and no legal sales have occurred, with retail not expected before fall 2026 at the earliest. Until sales begin, the end of 280E for Nebraska medical operators is theoretical, a benefit that attaches to revenue these businesses are not yet allowed to earn. It is also worth stressing what Schedule III does not do: it does not legalize cannabis, does not authorize interstate commerce, and does not shield state-licensed businesses from the Controlled Substances Act, so Nebraska's program remains federally illegal in substance even after the reschedule. https://nebraskaexaminer.com/2026/04/23/nebraska-advocates-cheer-as-doj-downgrades-medical-cannabis-to-schedule-iii-drug/ and https://nebraskaexaminer.com/2026/04/27/nebraska-supreme-court-hears-appeal-in-medical-cannabis-federal-preemption-case/ The broader DEA rescheduling hearing opened June 29, 2026 and may slip to 2027; any expansion beyond the medical category is unresolved. A separate reported development, possible addition of Nebraska to congressional appropriations-rider protections against DOJ interference (Nebraska had previously been left off that list), would reduce federal enforcement risk for the medical program but does not change the 280E or commerce analysis. https://nebraskaexaminer.com/2026/04/30/nebraska-medical-cannabis-laws-could-soon-be-protected-from-federal-interference-after-all/ and https://nebraskaexaminer.com/2026/02/16/nebraska-left-off-congressional-medical-cannabis-protections-prohibiting-doj-interference/

The November 12, 2026 hemp cliff. This is Nebraska's single largest federal exposure. The FY2026 agriculture appropriations language (Sec. 781, attributed in reporting to Rep. Andy Harris, R-MD; sponsor attribution unconfirmed against the enacted text) narrowed the federal definition of hemp to a total-THC standard capping finished consumable products at roughly 0.4 mg total THC per container, recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026. The proposed H.R.7010 delay was not enacted, and the 2026 Farm Bill (reported as H.R.7567; number unconfirmed against the enacted text) keeps the ban, so there is no federal off-ramp. https://www.congress.gov/crs-product/IN12620 and https://vicentellp.com/insights/2026-federal-hemp-ban-what-it-means-for-the-future-of-consumable-hemp-products/ Nebraska sits in a double bind. At the state level, LB316 (Sen. Kathleen Kauth, backed by AG Hilgers) would redefine hemp on a total-THC basis and ban most intoxicating products; it carried over into 2026 and its current status is unconfirmed, but the practical point is that the federal redefinition becomes the binding constraint regardless of whether LB316 passes. The practical effect: on November 12, 2026 the delta-8, delta-10, THCA, and HHC products now sold openly in Nebraska smoke shops and gas stations become federally non-compliant and exposed to Controlled Substances Act enforcement, and because Nebraska has built no protective state regime legalizing or regulating these products, there is no state framework to soften the landing. A carryover state ban plus the federal cap means Nebraska's intoxicating hemp sector is squeezed from both directions at once. https://nebraskaexaminer.com/2025/05/30/proposal-to-ban-most-thc-consumable-hemp-products-in-nebraska-delayed-until-at-least-2026/ and https://thehazeconnect.com/blogs/learn/november-12-2026-federal-hemp-deadline-every-state

Banking. SAFER Banking remains stalled in Congress, so even when Nebraska medical dispensaries open they will face the standard cannabis banking problem: limited access to depository institutions, payment processing, and ordinary lending, which raises costs and pushes operations toward cash. For a small, in-state, residency-gated operator pool (see below), the absence of normalized banking compounds the capital barrier. https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/

Psychedelics. Nebraska has no state psilocybin, MDMA, or ibogaine access law and none was located in 2026 (see Psychedelics section). Federally, psilocybin, MDMA, and ibogaine remain Schedule I; an April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority review vouchers are intended to fast-track FDA review, but there is no approval yet. The only realistic near-term access route for Nebraskans is therefore the federal FDA pathway, not state law, and that route has not yet produced an approved therapy.

Harm reduction. Nebraska allows naloxone (defined in 2025 LB195 to include naloxone and nalmefene, available by prescription, from a health professional, or over the counter) and permits fentanyl test strips to be sold over the counter and distributed by local public health departments, but it has no statewide syringe services program after Gov. Pillen vetoed the 2024 SSP bill (LB307) and the veto was sustained. https://www.rstreet.org/outreach/testimony-in-support-of-allowing-local-jurisdictions-to-authorize-syringe-services-programs-in-nebraska/ The relevant federal lever is the SAMHSA guidance of April 24, 2026, which bars federal funds for fentanyl test strips, clean syringes, and sterile water while continuing to support naloxone. The exposure: Nebraska programs and local health departments that rely on federal dollars to buy and distribute fentanyl test strips lose that funding stream, so a service Nebraska law permits may shrink for lack of federal support, while the one tool federal policy still backs, naloxone, is also the one Nebraska most fully embraces. Because Nebraska has no statewide syringe access to begin with, the federal cut to syringe and sterile-water funding lands on a base that was already near zero, but it forecloses federally funded expansion if a local opt-in bill such as LB165 were ever to pass.

Patient access and rights

This section covers what Nebraska law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026.

Hospital access (Ryan's Law): Nebraska has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Nebraska is not among them. The absence is the finding: a Nebraska patient has no enforceable right to use their medicine in a hospital today.

Broader protections: Nebraska is a special case. Voters approved medical cannabis at the ballot in November 2024, but the program is not yet operational, and adult-use remains illegal (a separate 2024 measure only narrowed possession penalties). So there is not yet a running medical program to speak of, and the law provides none of the six patient protections. For now the finding is a double absence: no operational program and no protections. This is a state to re-scan as the program stands up.

Out-of-state patients: with the program not operational, Nebraska recognizes no medical cards, its own or any other state's.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Nebraska has not enacted a Ryan's Law. The absence of the broader protections above is a feature of Nebraska law, not something federal rescheduling addresses.

Sources: Nebraska medical cannabis initiative, Neb. Rev. Stat. 71-24,105.

Related reading from Drug Policy Watch: the Federal Drug Policy Brief, the Schedule III rescheduling explainer, and the 50-State Matrix.

Analysis: the enclosure read in depth

Who is fenced out in Nebraska. The throughline is that Nebraskans voted decisively for medical cannabis (roughly 71% and 67% on the 2024 initiatives) and the state apparatus has responded by narrowing the opening as far as it can short of nullification. Several fences operate at once. First, contested implementation: the program is still tied up in litigation, with a Nebraska Supreme Court preemption appeal argued April 27, 2026 and not yet decided, and an AG and Governor who have both questioned the measures' validity, which keeps capital and physicians on the sidelines. https://nebraskaexaminer.com/2026/04/27/nebraska-supreme-court-hears-appeal-in-medical-cannabis-federal-preemption-case/ Second, restrictive draft regulations: a banned-product list (reportedly no raw plant material, no smoking or vaping products, no flavored items, no infused food or drink) shrinks the addressable market to a narrow set of forms. Third, a 4-year Nebraska residency and 51% U.S.-citizen ownership requirement that fences out multistate operators and most outside capital. Fourth, a one-dispensary-per-judicial-district cap that concentrates the few licenses geographically, chiefly around Omaha and Lincoln. Fifth, no home grow, so patients cannot self-supply. Sixth, AG opposition that has chilled in-state physician participation, leaving certified patients with possession rights but thin access to recommendations and, soon, dispensaries restricted to in-state recommendations. https://www.cann.dev/nebraska-cannabis-retail-february-2026/ and https://nebraskaexaminer.com/2026/04/13/medical-cannabis-regulations-now-headed-to-nebraska-ag-governor-for-approval/ The fenced-out groups are therefore out-of-state and undercapitalized operators, patients without an in-state physician relationship, home growers, and the entire intoxicating hemp sector facing the November cliff.

State-plus-federal interaction. The state and federal layers reinforce each other rather than offset. On cannabis, the federal Schedule III move offers Nebraska medical operators a 280E tax benefit, but the state has slow-walked the market so far that there are no sales to deduct against, so the federal gift arrives addressed to a business that does not yet exist; meanwhile stalled SAFER Banking leaves the same future operators cash-bound. On hemp, the federal November 12, 2026 redefinition does the heavy lifting the state LB316 ban aimed at, so even if LB316 stalls, Nebraska's intoxicating hemp market is foreclosed federally, and because Nebraska built no regulated state hemp lane, there is no domestic structure left standing. On harm reduction, federal SAMHSA cuts to syringe and test-strip funding land on a state that already declined to authorize syringe services, deepening rather than diverging from the state's restrictive posture. The net effect is enclosure by convergence: state restriction and federal enclosure point the same direction, fencing out small actors and hemp while leaving any future legal cannabis market in the hands of a few capitalized, in-state, license-holding incumbents, exactly the pattern the federal medicalize-and-control read favors.

What to watch. The Nebraska Supreme Court ruling on the preemption appeal; AG Hilgers' legal review and Gov. Pillen's final sign-off on the April 2026 formal regulations (delay pushes dispensary licensing past fall 2026); the July 3, 2026 signature deadline for the recreational constitutional initiative; the November 12, 2026 federal hemp effective date; the fate of LB316 and any revived provider-protection bill; and whether Nebraska is in fact added to congressional anti-interference protections.

The commons counter-move. Nebraska's offsetting force is the citizen initiative, the same mechanism that created the medical program over the political branches' objection. A 2026 measure to enshrine a constitutional right to use all plants in the genus Cannabis for adults 21 and older (filed August 18, 2025 by Bill Hawkins, the fifth recreational attempt since 2018) is in active signature gathering against a July 3, 2026 deadline, needing roughly 123,000 valid signatures with a 38-county distribution requirement. https://news.ballotpedia.org/2025/08/29/proponents-file-recreational-marijuana-initiative-in-nebraska-for-2026-ballot-the-fifth-initiative-attempt-since-2018/ and https://ballotpedia.org/Nebraska_Marijuana_Legalization_Initiative_(2026) If it qualifies and passes, a constitutional right would be far harder for the executive and AG to throttle than a statutory program, reopening the commons that the regulatory enclosure has been narrowing. No prior recreational attempt has qualified, so this remains a contingent counter-move rather than a settled one.

Justification for score 5/5 (corrected July 18, 2026; an earlier version of this brief held the score at 4). Voters approved medical cannabis by wide margins, yet executive and AG opposition, ongoing litigation, a chilled physician pool, a 4-year residency and 51% citizen-ownership rule, a one-per-district dispensary cap, a narrow product list, no home grow, no social equity, stalled SAFER Banking, and an imminent federal hemp crackdown combine to choke supply and access and to concentrate any eventual market in a few in-state hands, while federal SAMHSA cuts trim harm reduction. The federal layer reinforces rather than relieves the state enclosure. The earlier 4 rested on lawful patient possession, accessible naloxone and test strips, the live recreational initiative, and the theoretical Schedule III door. The July 2026 re-score corrected that reading: possession without any legal supply is not access, initiatives and reclassifications are prospects rather than access, and harm-reduction access, while real and recorded above, is not access to the plant commons this score measures. A market the voters created that the community still cannot enter is a fully enclosed market. If dispensaries actually open and patients can actually buy, the score will move with the facts.

Active legislation (2026)

This list is not exhaustive. Use the trackers for the long tail: the Nebraska Legislature site (https://nebraskalegislature.gov/), the Unicameral Update (https://update.legislature.ne.gov/).

Bill Title/Topic Chamber Status Sponsor(s)
LB1235 First medical cannabis implementing statute; lets the Medical Cannabis Commission set application fees, raise revenue, and require fingerprint background checks Unicameral Passed Legislature 46-2 (April 2026); governor signature unconfirmed General Affairs Committee, on behalf of the Medical Cannabis Commission at Gov. Pillen's request (per reporting)
LB933 Legal protections for health care providers who recommend medical cannabis Unicameral Advanced 30-7 on first round (March 2026); pulled April 2026 after hostile amendments; effectively stalled Sen. John Cavanaugh (Omaha)
LB316 Redefines hemp using a total-THC standard, effectively banning most intoxicating hemp products Unicameral 2026 carryover from 2025; current 2026 status unconfirmed Sen. Kathleen Kauth (Omaha), backed by AG Mike Hilgers
LB165 Would allow local jurisdictions to authorize syringe services programs Unicameral Introduced; 2026 status unconfirmed Unconfirmed (verify on legislature site)

Notes: Bill numbers, sponsors, vote counts, and statuses above are drawn from cited news reporting; the General Affairs Committee sponsorship of LB1235 and the precise 2026 status of LB316 and LB165 should be reconfirmed on the official tracker before publication. https://nebraskaexaminer.com/briefs/history-made-nebraska-legislature-passes-first-medical-cannabis-law-after-decade-delay/ and https://www.billtrack50.com/billdetail/1785559

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →

Sources